<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00964171</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000641759</org_study_id>
    <secondary_id>IB-PANTER</secondary_id>
    <secondary_id>IB 2008-33</secondary_id>
    <secondary_id>INCA-RECF0888</secondary_id>
    <secondary_id>EUDRACT-2008-004273-18</secondary_id>
    <nct_id>NCT00964171</nct_id>
  </id_info>
  <brief_title>Efavirenz as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer</brief_title>
  <official_title>A Phase II Trial to Assess the Efficacy of Efavirenz as Second-line Monotherapy for the Treatment of Advanced Pancreatic Adenocarcinomas.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Bergonié</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Efavirenz may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well efavirenz works as second-line therapy in&#xD;
      treating patients with metastatic pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Evaluate the efficacy of efavirenz as second-line monotherapy, in terms of&#xD;
           non-morphological progression at 2 months, in patients with metastatic adenocarcinoma of&#xD;
           the pancreas.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Evaluate non-morphological progression in these patients at 4 months.&#xD;
&#xD;
        -  Evaluate non-biological progression in these patients at 2 and 4 months.&#xD;
&#xD;
        -  Evaluate the quality of life of these patients at 2 and 4 months.&#xD;
&#xD;
        -  Evaluate the overall, progression-free, and event-free survival of these patients.&#xD;
&#xD;
        -  Evaluate the tolerability and safety profile of efavirenz in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral efavirenz once daily in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Patients complete quality-of-life questionnaires using the QLQ-C30 at baseline and at 2 and 4&#xD;
      months.&#xD;
&#xD;
      After completion of study therapy patients are followed up every 2 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2008</start_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non-morphological progression as defined by RECIST criteria</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-biological progression, defined as 2-month CA 19-9 concentration &lt; 1.5 times the baseline CA 19-9 concentration</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability and safety as assessed by NCI CTCAE v 3.0</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Pancreatic Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>efavirenz</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the pancreas&#xD;
&#xD;
               -  No other histological types&#xD;
&#xD;
          -  Radiologically confirmed metastatic disease in a non-irradiated area&#xD;
&#xD;
          -  Measurable disease according to RECIST criteria&#xD;
&#xD;
          -  Must have exhausted first-line gemcitabine hydrochloride chemotherapy&#xD;
&#xD;
          -  No CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WHO performance status (PS) 0-2 OR Karnofsky PS 70-100%&#xD;
&#xD;
          -  ANC ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
          -  Creatinine ≤ 1.25 times upper limit of normal&#xD;
&#xD;
          -  Alkaline phosphatase &lt; 5 times normal&#xD;
&#xD;
          -  Bilirubin &lt; 3 times normal&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Has French Social Security in compliance with the French law relating to biomedical&#xD;
             research&#xD;
&#xD;
          -  Able to comply with study treatment and follow-up&#xD;
&#xD;
          -  No severe renal failure&#xD;
&#xD;
          -  No severe hepatic impairment&#xD;
&#xD;
          -  No known hypersensitivity to the study drug and its excipients&#xD;
&#xD;
          -  No depression with a total score of ≥ 13 on the Hospital Anxiety and Depression (HAD)&#xD;
             scale&#xD;
&#xD;
          -  No active diarrhea that may affect the ability to absorb the study drug&#xD;
&#xD;
          -  No other cancer within the past 5 years except carcinoma in situ of the cervix or&#xD;
             basal cell carcinoma of the skin&#xD;
&#xD;
          -  No geographical, psychiatric, social, or psychological reason that would preclude&#xD;
             compliance with study procedures&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Recovered from all prior anticancer therapy&#xD;
&#xD;
          -  More than 30 days since prior investigational drugs and/or participation in a clinical&#xD;
             trial&#xD;
&#xD;
          -  Prior adjuvant chemotherapy (one-line only) and/or radiotherapy allowed&#xD;
&#xD;
          -  No prior enrollment on this study&#xD;
&#xD;
          -  No prior treatment acting on the signal transduction pathway&#xD;
&#xD;
          -  No prior yellow fever vaccine&#xD;
&#xD;
          -  No other concurrent second-line therapy&#xD;
&#xD;
          -  No concurrent terfenadine, astemizole, cisapride, midazolam, triazolam, pimozide,&#xD;
             bepridil, rye alkaloids, voriconazole, or St. John wort (Hypericum perforatum)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marianne Fonck, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Bergonié</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Fonck, MD</last_name>
      <phone>33-5-5633-3242</phone>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <study_first_submitted>August 21, 2009</study_first_submitted>
  <study_first_submitted_qc>August 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2009</study_first_posted>
  <last_update_submitted>April 6, 2010</last_update_submitted>
  <last_update_submitted_qc>April 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2010</last_update_posted>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <keyword>recurrent pancreatic cancer</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

